Posted: April 14, 2015 A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly...
Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A,...READ MORE
Posted: April 14, 2015 Impact of CR before and after allogeneic and autologous transplantation in...
Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini...READ MORE
Posted: April 14, 2015 Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and...
Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK.READ MORE
Posted: April 14, 2015 Phase 1/2 study of CDK4/6 inhibitor palbociclib (PD-0332991) with bortezomib...
Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S,...READ MORE
Posted: April 14, 2015 Risk stratification model in elderly patients with multiple myeloma: clinical...
Song MK, Chung JS, Lee JJ, Lee JH, Song IC, Lee SM, Shin DY, Lee GW, Lee IS.READ MORE
Posted: April 14, 2015 The investigational proteasome inhibitor ixazomib for the treatment of multiple...
Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S.READ MORE
Posted: April 14, 2015 Panobinostat: First Global Approval
Garnock-Jones KP.READ MORE
Posted: April 14, 2015 Smoldering multiple myeloma
Rajkumar SV, Landgren O, Mateos MV.READ MORE
Posted: April 14, 2015 New criteria for response assessment: role of minimal residual disease in...
Paiva B, van Dongen JJ, Orfao A.READ MORE
Posted: April 14, 2015 Bortezomib-based therapy combined with high cut-off hemodialysis is highly...
Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C,...READ MORE